To review the molecular mechanisms of androgen receptor (AR) reactivation in castration-resistant prostate cancer (CRPC) and discuss emerging therapeutic vulnerabilities, emphasizing the clinical implications of these findings.
Key Findings:
CRPC is characterized by persistent or reactivated AR signaling despite androgen deprivation, with significant clinical implications.
AR reactivation mechanisms include amplification, mutations, splice variants, and intratumoral androgen synthesis, which are critical for treatment resistance.
Epigenetic changes play a significant role in maintaining AR signaling and promoting aggressive tumor phenotypes, necessitating further research.
Emerging therapies targeting AR and associated pathways may improve treatment outcomes, highlighting the need for innovative strategies.
Interpretation:
CRPC is an adaptive state where tumor cells exploit various mechanisms to sustain AR signaling, indicating an urgent need for innovative treatment approaches that target these vulnerabilities.
Limitations:
The complexity of CRPC mechanisms may hinder the development of universally effective therapies, underscoring the need for personalized treatment strategies.
Variability in patient response to treatments complicates biomarker-guided therapy selection, necessitating further research.
Conclusion:
Understanding the mechanisms of AR reactivation and the role of epigenetics in CRPC can lead to more effective treatment strategies and improved patient outcomes, emphasizing the importance of ongoing research.
